CN112932737A - Drug-loaded degradable 3D printing sinus stent and preparation method thereof - Google Patents

Drug-loaded degradable 3D printing sinus stent and preparation method thereof Download PDF

Info

Publication number
CN112932737A
CN112932737A CN202110296453.3A CN202110296453A CN112932737A CN 112932737 A CN112932737 A CN 112932737A CN 202110296453 A CN202110296453 A CN 202110296453A CN 112932737 A CN112932737 A CN 112932737A
Authority
CN
China
Prior art keywords
sinus
dimensional
drug
printing
stent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110296453.3A
Other languages
Chinese (zh)
Other versions
CN112932737B (en
Inventor
刘杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou University
Original Assignee
Changzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou University filed Critical Changzhou University
Priority to CN202110296453.3A priority Critical patent/CN112932737B/en
Publication of CN112932737A publication Critical patent/CN112932737A/en
Application granted granted Critical
Publication of CN112932737B publication Critical patent/CN112932737B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/18—Internal ear or nose parts, e.g. ear-drums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y50/00—Data acquisition or data processing for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/002—Designing or making customized prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A61L2300/222—Steroids, e.g. corticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention discloses a drug-loaded degradable 3D printing sinus stent and a preparation method thereof. The invention takes degradable PLA material as raw material, adopts 3D printing technology, and fuses drug load into the process of 3D printing material forming. The drug release period of the stent is consistent with the material degradation period, the time requirement for wound healing after sinus dilation can be met, and the problem of short drug release time of a common drug-coated stent can be effectively solved. The nasal cavity and paranasal sinus degradable drug stent obtained by the invention can reduce mucosal inflammation and edema, promote mucosal healing, reduce scar formation and eliminate postoperative adhesion, thereby relieving the pain of patients and reducing the economic burden of the patients.

Description

Drug-loaded degradable 3D printing sinus stent and preparation method thereof
Technical Field
The invention discloses a drug-loaded 3D printing sinus stent and a preparation method thereof. The nasal cavity and paranasal sinus degradable drug stent obtained by the invention can reduce mucosal inflammation and edema, promote mucosal healing, reduce scar formation and eliminate postoperative adhesion, thereby relieving the pain of patients and reducing the economic burden of the patients.
Background
For common otorhinolaryngological diseases such as chronic nasosinusitis and nasal polyp, the current common operation method is a transnasal endoscopic operation, namely removing pathological changes, opening blocked sinus ostia and reconstructing and recovering physiological functions of nasal sinuses. However, this procedure is often less effective due to post-operative nasal adhesions and reocclusion of the sinus ostium.
In order to solve the problems, the invention discloses a drug-loaded 3D printing sinus stent which is implanted after a sinus dilation operation to prevent nasal cavity adhesion, and the drug can be continuously treated on a lesion position along with the release of the drug in the slow degradation process of the stent. This sinus support utilizes its holding power, can last strutting with physics support mode with the postoperative nasal cavity, utilizes the various required medicines direct action that load on this sinus support to be in the pathological change position when keeping nasal cavity air permeability, can realize the slow release of longer time even as required to give the medicine to the pathological change position and last the treatment, can avoid or reduce the use of oral medicine during implanting. The invention takes degradable PLA material as raw material, and fuses drug load into the process of 3D printing and forming of the material. The drug release period of the stent is consistent with the material degradation period, the time requirement for wound healing after sinus dilation can be met, and the problem of short drug release period of a common drug-coated stent can be effectively solved. The nasal cavity and paranasal sinus degradable drug stent obtained by the invention can reduce mucosal inflammation and edema, promote mucosal healing, reduce scar formation and eliminate postoperative adhesion, thereby relieving the pain of patients and reducing the economic burden of the patients.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a medicine-loaded 3D printing sinus stent.
The purpose of the invention is realized by the following technical scheme:
a preparation method of a drug-loaded degradable 3D printing sinus stent comprises the following steps:
(1) designing a three-dimensional structure of the sinus support and a two-dimensional grid structure after the sinus support is horizontally spread by utilizing CAD software to obtain the size and angle parameters of each part of the sinus support; converting the obtained three-dimensional sinus stent and the two-dimensional grid structure parameters thereof into an STL format and inputting the STL format into a 3D printer;
(2) selecting polylactic acid (PLA) as a main raw material according to the parameters input in the step (1), obtaining a two-dimensional PLA mesh material with a stable structure through a 3D printing process, wherein a carrier substrate formed by printing the two-dimensional PLA mesh material is a multi-rhombus mesh groove template which is designed in advance, and placing medicine components with loads in the multi-rhombus mesh groove template before printing the two-dimensional PLA mesh material; the loading process of the medicine is combined with the 3D printing and forming process of the two-dimensional PLA mesh material in the step (2), so that the medicine in the multi-diamond mesh groove template in the step (2) can be fully contacted with the material;
(3) bonding the upper end face and the lower end face of the two-dimensional PLA grid material loaded with the medicine obtained in the step (2) to obtain a medicine-carrying sinus stent with a three-dimensional grid structure;
(4) and (4) reinforcing the crossed part of the medicine-carrying sinus stent obtained in the step (3) to obtain the medicine-carrying 3D printing sinus stent.
Further, the three-dimensional sinus support in the steps (1) and (2) contains 8-15 diamond grid units when being horizontally laid and unfolded into a two-dimensional grid structure.
Further, the side length of the rhombic grid in the step (2) is 9-15 mm.
Further, the molecular weight of the PLA in the step (2) is 50000 to 250000.
Further, the medicine in the step (2) is mometasone furoate, moxifloxacin hydrochloride or ampicillin.
Further, the bonding and reinforcing processes in the steps (3) and (4) adopt PLA melt bonding treatment.
Compared with the traditional medicine carrying mode of spraying medicines on the surface of the stent, the degradable medicine carrying stent material obtained by the invention can more uniformly disperse the medicines into the whole material system, the release of the medicines is gradually realized along with the slow degradation of the material, the medicine utilization rate and the effective period of the PLA medicine carrying stent are effectively improved, and the invention has obvious superiority.
Detailed Description
The invention will be further described with reference to the following examples for a better understanding of the invention, but the scope of the invention as claimed is not limited to the scope represented by the examples mentioned.
Example 1
PLA is used as a raw material, mometasone furoate is used as an auxiliary medicine, and a medicine-loaded 3D printing sinus stent is prepared by a 3D printing technology. The preparation method of the degradable nasal sinus stent comprises the following steps:
(1) designing a three-dimensional structure of the sinus support and a two-dimensional grid structure after the sinus support is horizontally spread by utilizing CAD software to obtain parameters such as the size, the angle and the like of each part of the support material; converting the obtained three-dimensional sinus stent and the two-dimensional grid structure parameters thereof into an STL format and inputting the STL format into a 3D printer;
(2) selecting PLA with the molecular weight of 100000 as a main raw material according to the parameters input in the step (1), preparing a two-dimensional PLA grid material with 12 continuous rhombic grids through a 3D printing process, wherein the side length of each grid is 10mm, a carrier substrate for material printing and forming is a groove template formed by continuous rhombic grids with the same size, and sufficient mometasone furoate medicine is placed in the groove template of the grids before printing;
(3) the loading process of the mometasone furoate drug is combined with the 3D printing and forming process of the PLA material, so that the drug in the template in the step (2) can be fully contacted with the PLA material;
(4) bonding two ends of the diamond grid stent material loaded with the mometasone furoate drug obtained in the step (3) to obtain a drug-loaded sinus stent with a three-dimensional grid structure;
(5) and (5) adopting PLA to melt, bond and reinforce the crossed part of the PLA grid paranasal sinus stent obtained in the step (4), and obtaining the drug-loaded 3D printing paranasal sinus stent.
Example 2
PLA is used as a raw material, moxifloxacin hydrochloride is used as an auxiliary drug, and a drug-loaded 3D printing sinus stent is prepared by a 3D printing technology. The preparation method of the degradable nasal sinus stent comprises the following steps:
(1) designing a three-dimensional structure of the sinus support and a two-dimensional grid structure after the sinus support is horizontally spread by utilizing CAD software to obtain parameters such as the size, the angle and the like of each part of the support material; converting the obtained three-dimensional sinus stent and the two-dimensional grid structure parameters thereof into an STL format and inputting the STL format into a 3D printer;
(2) selecting PLA with the molecular weight of 150000 as a main raw material according to the parameters input in the step (1), preparing a two-dimensional PLA grid material with 10 continuous rhombic grids through a 3D printing process, wherein the side length of the grids is 10mm, a carrier substrate formed by material printing is a groove template formed by continuous rhombic grids with the same size, and placing sufficient moxifloxacin hydrochloride in the groove template of the grids before printing;
(3) combining the loading process of the moxifloxacin hydrochloride medicine into the 3D printing and forming process of the PLA material, and ensuring that the medicine in the template in the step (2) can be fully contacted with the PLA material;
(4) bonding two ends of the diamond grid stent material loaded with the moxifloxacin hydrochloride drug obtained in the step (3) to obtain a drug-loaded sinus stent with a three-dimensional grid structure;
(5) and (5) adopting PLA to melt, bond and reinforce the crossed part of the PLA grid paranasal sinus stent obtained in the step (4), and obtaining the drug-loaded 3D printing paranasal sinus stent.

Claims (7)

1. A preparation method of a drug-loaded degradable 3D printing sinus stent is characterized by comprising the following steps:
(1) designing a three-dimensional structure of the sinus support and a two-dimensional grid structure after the sinus support is horizontally spread by utilizing CAD software to obtain the size and angle parameters of each part of the sinus support; converting the obtained three-dimensional sinus stent and the two-dimensional grid structure parameters thereof into an STL format and inputting the STL format into a 3D printer;
(2) selecting polylactic acid (PLA) as a main raw material according to the parameters input in the step (1), obtaining a two-dimensional PLA mesh material with a stable structure through a 3D printing process, wherein a carrier substrate formed by printing the two-dimensional PLA mesh material is a multi-rhombus mesh groove template which is designed in advance, and placing medicine components with loads in the multi-rhombus mesh groove template before printing the two-dimensional PLA mesh material; the loading process of the medicine is combined with the 3D printing and forming process of the two-dimensional PLA mesh material in the step (2), so that the medicine in the multi-diamond mesh groove template in the step (2) can be fully contacted with the material;
(3) bonding the upper end face and the lower end face of the two-dimensional PLA grid material loaded with the medicine obtained in the step (2) to obtain a medicine-carrying sinus stent with a three-dimensional grid structure;
(4) and (4) reinforcing the crossed part of the medicine-carrying sinus stent obtained in the step (3) to obtain the medicine-carrying 3D printing sinus stent.
2. The method of claim 1, wherein the three-dimensional sinus support of steps (1) and (2) comprises 8-15 diamond-shaped lattice cells when horizontally laid into a two-dimensional lattice structure.
3. The preparation method of claim 1, wherein the side of the rhombic grid in the step (2) is 9-15 mm.
4. The method of claim 1, wherein the molecular weight of the PLA in the step (2) is 50000 to 250000.
5. The process according to claim 1, wherein the drug in step (2) is mometasone furoate, moxifloxacin hydrochloride or ampicillin.
6. The method of claim 1, wherein the bonding and reinforcing processes in steps (3) and (4) are performed by using a PLA fusion bonding process.
7. A drug-loaded degradable 3D printed sinus stent, characterized in that the drug-loaded degradable 3D printed sinus stent is prepared by the preparation method of any one of claims 1-6.
CN202110296453.3A 2021-03-19 2021-03-19 Drug-loaded degradable 3D printing sinus stent and preparation method thereof Active CN112932737B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110296453.3A CN112932737B (en) 2021-03-19 2021-03-19 Drug-loaded degradable 3D printing sinus stent and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110296453.3A CN112932737B (en) 2021-03-19 2021-03-19 Drug-loaded degradable 3D printing sinus stent and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112932737A true CN112932737A (en) 2021-06-11
CN112932737B CN112932737B (en) 2022-07-19

Family

ID=76226819

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110296453.3A Active CN112932737B (en) 2021-03-19 2021-03-19 Drug-loaded degradable 3D printing sinus stent and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112932737B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712617A (en) * 2023-05-15 2023-09-08 深圳市荔辉医疗科技有限公司 Degradable carbon skeleton hydrogel sinus stent and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437471A (en) * 2006-04-12 2009-05-20 动脉再造技术股份有限公司 Methods of polymeric stent surface smoothing and resurfacing to reduce biologically active sites
KR20180121710A (en) * 2017-04-28 2018-11-08 포항공과대학교 산학협력단 Medical stent based on 3d printing and printing method thereof
CN110641012A (en) * 2019-09-25 2020-01-03 青岛五维智造科技有限公司 Micro-scale 3D printing preparation method and device for polymer fully-degradable intravascular stent and application of micro-scale 3D printing preparation method and device
CN111529150A (en) * 2020-04-28 2020-08-14 东南大学苏州医疗器械研究院 Sinus duct stent and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437471A (en) * 2006-04-12 2009-05-20 动脉再造技术股份有限公司 Methods of polymeric stent surface smoothing and resurfacing to reduce biologically active sites
KR20180121710A (en) * 2017-04-28 2018-11-08 포항공과대학교 산학협력단 Medical stent based on 3d printing and printing method thereof
CN110641012A (en) * 2019-09-25 2020-01-03 青岛五维智造科技有限公司 Micro-scale 3D printing preparation method and device for polymer fully-degradable intravascular stent and application of micro-scale 3D printing preparation method and device
CN111529150A (en) * 2020-04-28 2020-08-14 东南大学苏州医疗器械研究院 Sinus duct stent and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712617A (en) * 2023-05-15 2023-09-08 深圳市荔辉医疗科技有限公司 Degradable carbon skeleton hydrogel sinus stent and preparation method thereof
CN116712617B (en) * 2023-05-15 2024-02-02 深圳市荔辉医疗科技有限公司 Degradable carbon skeleton hydrogel sinus stent and preparation method thereof

Also Published As

Publication number Publication date
CN112932737B (en) 2022-07-19

Similar Documents

Publication Publication Date Title
CN110141760B (en) Centrum forming expansion balloon with drug loaded on surface and preparation method thereof
US11559413B2 (en) Anti-migration micropatterned stent coating
CN108969165B (en) 4D printing shape memory polymer composite material tracheal stent and preparation method thereof
CN112932737B (en) Drug-loaded degradable 3D printing sinus stent and preparation method thereof
CN103501852B (en) The manufacture method of microstructured bodies
JP2013532025A5 (en)
CA2457189A1 (en) Medical devices comprising nanomaterials and therapeutic methods utilizing the same
CN103393459B (en) Locking jaw face rebuilding type bone-setting plate
US20170216008A1 (en) Method and apparatus for creating a reconstructive graft
CN104689373A (en) Bioactive bone repair material containing williams elder twig as well as preparation method and application thereof
CN106859817A (en) A kind of 3D printing personalization caged dentistry bone grafting guide plate
CN107510884A (en) A kind of Silica hydrogel elasticity scar plaster and preparation method thereof
Hart et al. Reconstruction of alveolar defects using titanium-reinforced porous polyethylene as a containment device for recombinant human bone morphogenetic protein 2
CN103251983B (en) Method for preparing spliced artificial bone-filled sustained-release material with treatment effect
CN102302386B (en) Preparation method of slow-releasing drug type bionic bone scaffold
CN111529150A (en) Sinus duct stent and preparation method thereof
AU2020260132A1 (en) Biodegradable nasal splint
CN102697548B (en) Method for preparing novel individual degradable artificial intraosseous stent
US20110262518A1 (en) Treatment for cardiac injuries created by myocardial infarction
CN111228578A (en) Drug-loaded silk fibroin bone repair screw and preparation method thereof
CN203898412U (en) Fixing device for department of orthopaedics
WO2016107108A1 (en) Polylactic acid nerve scaffold and manufacturing method therefor
CN103751838B (en) The preparation method of a kind of year VEGF porous hydroxyapatite support
CN103463679B (en) A kind of hernia mesh plug prepared with modified polypropylene fiber filaments screen cloth
CN206518717U (en) A kind of artificial periosteum for foot Bone Defect Repari

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant